Anadis goes over
Friday, 06 June, 2008
Victorian biotech Anadis (ASX: ANX) has sold over $820,000 worth of new shares to its shareholders under its share purchase plan (SPP), raising over $70,000 more than was intended.
The company, which specialises in polyclonal antibodies, said it had originally only intended to raise $750,000 under the SPP, but because of overwhelming interest decided to sell more, raising $823,000.
The new funds will be used to help fund clinical trials, and ultimately commercialise new products, the company said.
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
